Launch of the WVPA-Ceva joint Digital Library >
Launch of a digital library resource on poultry veterinary medicine
Ceva completes deal to acquire portfolio of Merial swine & cattle vaccines and nonsteroidal anti-inflammatories from Boehringer Ingelheim >
19 January 2017: Ceva Santé Animale today completed the acquisition of a diversified portfolio of products, including swine and cattle vaccines and multi-species nonsteroidal anti-inflammatories from Boehringer Ingelheim following its acquisition of Merial Animal Health. All the products will be immediately available through local Ceva companies or its distributors, with no interruption of supply....
Ceva acquires Hertape and Inova to enter Brazil’s top 5 animal health companies >
Move will increase the group global vaccine footprint with significant entry into the ruminant, Foot and Mouth disease market and a first entry into companion animal vaccines.
Ceva Santé Animale given European Commission go ahead to acquire Merial assets from Boehringer Ingelheim >
The European Commission recently gave its approval for the transfer to Ceva Santé Animale of nine products developed and currently marketed by Merial.
C.H.I.C.K Program receives the 1st independently audited quality recognition >
For the first time, an AH company services program receives internationally recognized quality approval from Bureau Veritas.
Ceva sponsors IAHAIO Conference held in Paris >
Ceva reiterates its commitment to promoting the benefits of human-animal interaction (HAI)
Ceva posts strong double-digit organic growth once again in first half of 2016 >
Ceva sponsors the International Symposium on Marek’s Disease and Avian Herpes viruses organised by INRA, France >
11th International Symposium on Marek’s Disease and Avian Herpes viruses organized in Tours, France
Avian Flu - Ceva's reveals plans to develop new AI H7 vaccine during latest summit in Mexico >
Ceva gathered experts from around the world to share the latest findings on the global threat posed by Avian Influenza (AI)
Ceva acquires Biovac, leading French manufacturer of Autogenous vaccines >
Move will reinforce group’s AMR strategy to find alternative solutions to use of antibiotics